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Retinoblastoma, a rare tumor arising from the retina, is the most common primary intra-ocular malignancy in childhood and infancy. 
Worldwide, the incidence of retinoblastoma varies sig-
nificantly. Rates as low as 3.4 and as high as 42.5 cases 
per million have been previously reported.1,2 Treatment 
alternatives include focal therapies such as laser photo-
coagulation, transpupillary thermotherapy, cryothera-
py and plaque therapy, chemotherapy, enucleation and 
external beam radiotherapy. In developing countries, 
prognosis varies according to disease stage. Localized 
disease has excellent prognosis with long-term sur-
vival. On the other hand, metastatic retinoblastoma 
is an aggressive disease with dismal prognosis.3 Data 
addressing the national epidemiological characters of 
retinoblastoma are generally lacking in the Middle 
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BACKGROUND AND OBJECTIVE: the epidemiological characteristics of retinoblastoma have been extensively 
studied in developed countries, however epidemiological data is scarce in the middle East. We present a de-
tailed epidemiological analysis of retinoblastoma in Jordan in an attempt to aid national and regional strategies 
for improved cancer surveillance and control.  
DESIGN AND SETTING: retrospective review of retinoblastoma cases presenting to the sole and exclusive 
ocular oncology referral center in Jordan. 
PATIENTS AND METHODS: forty children (59 eyes) presenting with clinically and/or histologically confirmed 
retinoblastomas were treated at King hussein Cancer Center (amman, Jordan) between January 2006 and 
December 2010. this case series included 28 boys and 12 girls. Data relating to age at diagnosis, laterality, 
gender, treatment modality and survival were recorded. 
RESULTS: the mean age-adjusted incidence of retinoblastoma in Jordan was 9.32 cases per million children per 
year for children aged 0-5 years. the male: female ratio was 2.3:1. Bilateral cases were encountered in 19 pa-
tients (47.5%) while 21 patients (52.5%) harbored unilateral retinoblastoma. at the time of follow-up, 38 patients 
(95%) were alive. overall, 40 eyes (67.8%) were successfully preserved without the need for enucleation. 
CONCLUSIONS: the national epidemiological data gathered in this study indicates that the incidence of retino-
blastoma in Jordan is similar to that reported in various countries of the world. Jordanian boys, however, are at 
significantly higher risk for developing retinoblastoma than age-matched girls. furthermore, Jordanian patients 
are more likely to harbor bilateral retinoblastoma. 
East. We present a detailed epidemiological analysis of 
retinoblastoma in Jordan. 
PATIENTS AND METHODS 
Data from our hospital-based cancer registry address-
ing the period from January 2006 to December 2010 
were analyzed. Charts of consecutive patients with 
a clinical and/or histopathological diagnosis of reti-
noblastoma treated at King Hussein Cancer Center 
(Amman, Jordan) were retrospectively reviewed follow-
ing acquisition of KHCC institutional review board 
approval. Furthermore, research presented in this study 
was conducted in adherence to the guidelines of the 
Declaration of Helsinki. Only Jordanian pediatric pa-
tients with a diagnosis of retinoblastoma were included 
in this case series. Details relating to the date of presen-
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tation, age at presentation, laterality, treatment modal-
ity and outcome were recorded. 
Since 2006, the ocular oncology division at KHCC 
has been the sole and exclusive referral center for all ret-
inoblastoma cases in Jordan. A multidisciplinary team 
consisting of a pediatric ophthalmologist, pediatric 
medical oncologists and radiation oncologist assesses 
patients. Retcam (Clarity Medical Systems, Pleasanton, 
CA, USA) is available at our center for assessment of 
these patients. As such, our data actually represents 
the entire pool of patients in Jordan during this pe-
riod. Age-specific incidence rates were expressed per 
1 000 000 children. Qualitative data were tested using 
the chi-square test. A P value ≤.05 was considered sta-
tistically significant. Statistical analysis was performed 
using SAS version 9.1 (SAS Institute Inc, Cary, NC).
RESULTS 
Forty retinoblastoma patients (59 eyes) were identified 
of which 16 eyes (27.1%) demonstrated pathological 
confirmation of the diagnosis following enucleation. 
This study included 28 (70%) boys and 12 (30%) girls. 
The incidence of retinoblastoma was 9.32 cases per mil-
lion children per year in children under 5 years of age 
and 3.73 per million children per year in children un-
der 15 years of age (Table 1). There was no significant 
change in the incidence of retinoblastoma over the years 
(Figure 1). Data regarding family history were available 
in 35 patients of whom 6 (17.1%) demonstrated a posi-
tive family history of disease. Thirty-seven cases (92.5%) 
were diagnosed prior to 5 years of age of whom 21 cases 
(52.5%) were diagnosed during the infant’s first year of 
life. Twenty-one patients (52.5%) harbored unilateral 
disease of whom 11 patients (52.4%) exhibited involve-
ment of the right eye and 10 patients (47.6%) the left 
eye while 19 patients (47.5%) harbored bilateral retino-
blastomas. Bilateral retinoblastoma cases were detected 
at a younger age than unilateral cases. All bilateral cases 
were diagnosed prior to 2 years of age as opposed to 12 
unilateral cases (57.1%) diagnosed prior to 2 years of 
age (Figure 2). 
Five patients (12.5%) received no treatment of whom 
two refused treatment and subsequently died due to dis-
ease and three were lost to follow-up. For the remaining 
cases, 17 patients (42.5%) were treated by a combina-
tion of cytoreductive chemotherapy and focal therapy, 8 
(20%) were treated by enucleation and adjuvant chemo-
therapy, 7 (17.5%) were treated by enucleation alone, 
2 (5%) were treated by chemotherapy alone while 1 
(2.5%) patient received enucleation, chemotherapy and 
radiotherapy. Overall, 16 patients (40%) were treated 
by enucleation. Thirteen unilateral cases (61.9%) ended 
with enucleation as opposed to 3 bilateral cases ending 
with enucleation (15.8%) (Figure 3). At the time of fol-
low-up, 38 children (95%) were alive. 
Among various variables tested, only laterality had 
a significant effect on the choice of treatment. Patients 
presenting with unilateral disease were more likely to be 
treated by enucleation than those with bilateral disease 
(P=.003).
DISCUSSION 
Worldwide, incidence rates for retinoblastoma in chil-
dren aged 0-4 years vary from a low of 3.4 per million 
reported in Bulgaria to a high of 42.5 per million re-
ported in Mali.1,2 Due to the scarcity of published data, 
incidence rates vary greatly within Asia (from 6.3 to 19.6 
per million), Africa (from 10.6 to 42.5 per million) and 
Table 1.  age-specific incidence of newly diagnosed patients with retinoblastoma.
Age group at 
diagnosis in 
years
No. % Children/year at risk [4]
Incidence 
(rate/million/
year)
<1 21 52.5 170 000 24.7
1-2 10 25 165 600 12.1
2-3 2 5 157 800 2.5
3-5 4 10 300 000 1.3
5-15 3 7.5 1 350 000 0.4
Total 40 100 2 143 400 3.7
Figure 1. number of cases diagnosed by year
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South America (from 7 to 17.1 per million). In Europe, 
Australia and the United States, incidence rates show less 
variability at 6-12, 10.3 and 11.8 per million, respective-
ly.3-5 Chantada et al6 compared patients with familial reti-
noblastoma from five centers in developing countries to a 
reference center in the US. Although five patients from 
Jordan were included in this study, this report does not 
represent an epidemiological assessment of retinoblasto-
ma in Jordan. Furthermore, to the best of our knowledge, 
there is only one published report addressing the national 
incidence of retinoblastoma in a Middle Eastern country 
(Table 2).7
Since KHCC is the sole and exclusive referral center 
for retinoblastoma cases in our country, our results actu-
ally represent the entire pool of retinoblastoma cases in 
Jordan. In our study, the mean annual incidence of reti-
noblastoma in Jordan was found to be 9.32 per million 
children under the age of 5 years. This rate is similar to 
incidence rates previously reported in the US, northern 
Europe, Singapore and Oman.7,16-18 However, highlight-
ing the temporal trend of a rare disease such as retino-
blastoma can prove difficult since random discrepancies 
from year to year will inevitably produce wide variations 
in the annual incidence rates. A such, whether the annual 
incidence rate in Jordan will remain stable over time is un-
known, as it is in a number of countries worldwide.17,19-23
In our report, 21 children (52.5%) harbored uni-
lateral while 19 children (47.5%) harbored bilateral 
retinoblastomas, which differs from North American 
and European reports, which state that sporadic retino-
blastoma constitutes approximately 70% of cases.3,24,25 
Out of a pool of 833 patients reported in eight studies 
from various Middle Eastern countries and India, 530 
(63.6%) harbored unilateral retinoblastoma.7-12,14,15 As 
such, we report a relatively high rate of bilateral disease 
in our study population. Since patients with bilateral 
retinoblastoma typically exhibit genetic predisposition, 
this observation might be explained by consanguineous 
marriage, which is customary in Jordan. Furthermore, 
large-sized families, which are prevalent in Jordan, 
would pose an increased risk of having a second, third 
or even higher number of children with bilateral retion-
blastomas. Six patients (17.1%) demonstrated a positive 
family history of retinoblastoma in our population. 
Worldwide, reports indicate an equal male to female 
distribution of retinoblastoma cases. The male female 
ratio ranges from 1 to 1.12 in the US.26 The male female 
ratio in a large pool of retinoblastoma cases (852 pa-
tients) reported in various Middle Eastern and Indian 
studies is 1.09:1.7-15 However, our series showed that 
the male female ratio for retinoblastoma in children 
aged 0 to 15 was 2.3:1 (P=.016). Further epidemio-
logical and genetic studies are necessary to explain this 
rather unexpected finding.  
Prior to 2006, several gaps hindered the provision 
of comprehensive quality care for Jordanian retinoblas-
toma patients outside our institution, including inap-
propriate clinical practices, insufficient implementation 
of evidence-based medicine and unbalanced physical 
distribution of well-trained care providers.27 As a con-
sequence, most patients were diagnosed at an advanced 
stage. Moreover, due to the lack of adequate physician 
training in the delivery of focal therapy, enucleation was 
the only option for curing these children. Since 2006, 
KHCC has emanated as the sole and exclusive refer-
ral center for all retinoblastoma cases in Jordan. Care is 
delivered via a multidisciplinary approach and is heav-
Figure 2. distribution of retinoblastoma by laterality and age at diagnosis
Figure 3. Treatment modalities for 40 retinoblastoma cases.
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ily evidence-driven. Furthermore, nearly all therapeutic 
alternatives are available to our patients including focal 
surgical approaches via laser photocoagulation, transpu-
pillary thermotherapy and cryotherapy, focal irradiation 
via plaque therapy, 3D conformal external-beam radio-
therapy and enucleation. Secondary to such carefully 
planned healthcare delivery, our results are consistent 
with those reported in the West.3, 24-26
The incidence of retinoblastoma in Jordan is similar 
to that reported in Oman and various Western coun-
tries. Jordanian boys, however, are at a significantly high-
er risk of developing retinoblastoma than age-matched 
girls. Furthermore, Jordanian patients are more likely 
to harbor bilateral retinoblastoma probably reflecting a 
higher incidence of inherited disease. We believe that 
further epidemiological and genetic studies are neces-
sary to confirm these findings. 
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